New treatment approach for Fanconi anemia using enzymes
Evaluating a Novel Enzymatic Modality for the Treatment of Fanconi Anemia
This study is looking at a new treatment for kids with Fanconi anemia that uses special enzymes to help reduce harmful substances in the body, aiming to improve their blood health and overall well-being.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Kinetiq Therapeutics LLC NIH-funded |
| Lab location | 1 site (Fort Worth, United States) |
| Project ID | NIH-11005464 on NIH RePORTER |
What this research studies
This research focuses on developing a novel enzymatic treatment for Fanconi anemia, a genetic disorder that leads to severe bone marrow failure and increased cancer risk in children. The study aims to explore how specific enzymes can counteract the toxic effects of aldehydes, which are harmful byproducts of DNA damage. By targeting these toxic substances, the research seeks to improve hematopoietic (blood-forming) function and overall patient health. The approach is innovative as it addresses the root causes of the disease rather than just managing symptoms.
Who could benefit from this research
Good fit: Ideal candidates for this research are children aged 0-11 years diagnosed with Fanconi anemia.
Not a fit: Patients with other forms of bone marrow failure or those outside the specified age range may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new therapeutic option that improves survival and quality of life for children with Fanconi anemia.
How similar studies have performed: While there have been emerging strategies for treating Fanconi anemia, this enzymatic approach is novel and has not been extensively tested in clinical settings.
Where this research is happening
Fort Worth, United States
- Kinetiq Therapeutics LLC — Fort Worth, United States (Active)
Researchers
- Principal investigator: Cao, Mingju — Kinetiq Therapeutics LLC
- Study coordinator: Cao, Mingju
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.